Welcome to our dedicated page for CollPlant Biotechnologies SEC filings (Ticker: CLGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CollPlant Biotechnologies Ltd. filings document foreign private issuer current reports for a regenerative and aesthetic medicine company built around plant-derived rhCollagen. Form 6-K reports cover operating and financial results, corporate updates on BioInk, Collink.3D, BioFlex, Vergenix STR and photocurable dermal filler technology, as well as intellectual-property disclosures and collaboration-related material events.
The filing record also documents capital-structure matters involving ordinary shares and warrants, Nasdaq Capital Market bid-price compliance notices, and material agreements. Certain 6-K reports are incorporated by reference into the company’s Form S-8 and Form F-3 registration statements, linking current-event disclosures to equity compensation and shelf-registration records.
CollPlant Biotechnologies Ltd received an ownership update as a Loewenbaum-led group and related entities reported a combined beneficial holding of 3,518,237 Ordinary Shares, representing 18.6% of the company’s 18,908,207 outstanding Ordinary Shares as of March 31, 2026.
On June 29, 2026, The Loewenbaum 1992 Trust entered into a Securities Purchase Agreement with CollPlant for 1,764,706 Ordinary Shares, Series A Warrants to purchase 1,764,706 shares, and Series B Warrants to purchase 3,529,412 shares, a transaction completed on July 6, 2026. Both warrant series have an exercise price of $0.34 per share and become exercisable only after shareholder approval expected on or about July 29, 2026; the Series A Warrants expire July 16, 2028 and the Series B Warrants expire July 16, 2031. The 18.6% figure includes shares potentially issuable within 60 days under existing options and warrants, but excludes shares underlying these new Warrants until they become exercisable.
CollPlant Biotechnologies Ltd conducted an exempt private securities offering under Rule 506(b) of Regulation D. The notice reports a total amount sold of $10,400,000, including the exercise price of ordinary shares underlying warrants with an exercise price of $0.34, with no remaining amount offered.
The securities consist of equity, Series A and Series B warrants to purchase ordinary shares, and the underlying ordinary shares issuable upon exercise. H.C. Wainwright & Co., LLC acted as placement agent and received fees, expense reimbursements, and placement agent warrants. CollPlant intends to use net proceeds for general corporate purposes, including working capital, R&D programs, and evaluating strategic business combinations and other strategic transactions.
CollPlant Biotechnologies Ltd. is registering for resale by existing investors up to 31,047,068 ordinary shares. These comprise 4,464,707 PIPE Shares and 26,582,361 shares issuable upon exercise of pre-funded, Series A, Series B and placement agent warrants issued in a June–July 2026 private placement.
The company will not receive proceeds from Selling Shareholders’ resales but may receive up to $8.0 million in gross proceeds if all warrants are exercised for cash, to be used for general corporate purposes, working capital, R&D and evaluating strategic combinations. As of March 31, 2026, 14,443,500 shares were outstanding, increasing to 18,908,207 on an as-adjusted basis after the PIPE, which generated approximately $2.3 million in net proceeds.
CollPlant develops rhCollagen-based products for regenerative and aesthetic medicine, including dermal fillers and 3D-bioprinted breast implants. The company reports ongoing losses, negative operating cash flows, and states its current cash resources are not sufficient for the next 12 months, raising substantial doubt about its ability to continue as a going concern absent additional financing.
CollPlant Biotechnologies Ltd. files a Form F-3 prospectus to register 31,047,068 ordinary shares for resale by selling shareholders.
The registration covers 4,464,707 PIPE Shares and 26,582,361 ordinary shares issuable upon exercise of warrants issued in a June 29, 2026 private placement that closed on July 6, 2026. The prospectus states the Company will not receive proceeds from resales but would receive cash if warrants are exercised; full cash exercise of the outstanding warrants would yield approximately $8.0 million.
CollPlant Biotechnologies Ltd. is calling an extraordinary general meeting to seek shareholder approval for a major increase in its authorized share capital. The proposal would raise authorized Ordinary Shares from 30,000,000 to 500,000,000, each with a par value of NIS 1.50, and amend the Memorandum and Articles of Association accordingly.
The Board states this larger capacity would support obligations from private placement agreements signed in June 2026, which involve units of shares and warrants, and provide flexibility for future strategic transactions. Shareholders of record on July 9, 2026 may vote at the July 29, 2026 meeting in Tel-Aviv.
As of July 6, 2026, 18,908,207 Ordinary Shares were outstanding, excluding 18,409 held in treasury, each carrying one vote. A quorum requires at least 20% of outstanding Ordinary Shares present in person or by proxy, and the Board recommends voting in favor of the proposal.
CollPlant Biotechnologies entered into a definitive securities purchase agreement for a $2.6 million private placement. The deal covers 7,647,061 ordinary shares (or pre-funded warrants in lieu) plus unregistered series A and series B warrants, all priced at $0.34 per share and accompanying warrants (or $0.3399 per pre-funded warrant and accompanying warrants).
The series A and B warrants each have a $0.34 exercise price, become exercisable on the shareholder approval date, and have terms of two and five years, respectively, after effectiveness of a resale registration statement. CollPlant plans to use the net proceeds for general corporate purposes, working capital, research and development, and to continue evaluating strategic business combinations.
H.C. Wainwright & Co. is acting as exclusive placement agent and will receive cash fees, expense reimbursements, and placement agent warrants to purchase up to 458,824 ordinary shares at $0.425 per share. The securities are being issued in a private placement under U.S. Securities Act exemptions, with CollPlant agreeing to file a resale registration statement for the shares and warrant shares.
CollPlant Biotechnologies reported weak first quarter 2026 results and outlined strategic and R&D updates. Revenue fell to $73,000 from $2.055 million a year earlier, mainly because a $2.0 million milestone payment in Q1 2025 did not repeat. GAAP net loss widened to $3.1 million, or $0.23 per share, versus a $1.5 million loss, or $0.13 per share, in Q1 2025. Cash and cash equivalents were $4.3 million as of March 31, 2026, with $3.0 million used in operating activities in the quarter.
The company implemented a cost reduction plan, cutting headcount by about 50%, which helped lower operating expenses to $2.9 million from $3.5 million. CollPlant is advancing a next-generation photocurable dermal filler platform in final preclinical stages and launched its BioFlex rhCollagen-based bioprinting kit. Management also began evaluating strategic alternatives, including potential acquisitions, strategic transactions and other business combinations, with no decisions or timetable yet.
CollPlant Biotechnologies Ltd director Hugh M. Evans filed an initial ownership report showing his equity stake in the company. He directly holds 315,554 Ordinary Shares and 10,000 Restricted Share Units, of which 3,125 are vested and 6,875 vest in eleven equal quarterly installments from March 25, 2026 through September 25, 2028, subject to continued service.
Evans also holds two option awards to purchase Ordinary Shares: 24,000 options and 23,000 options, each with an exercise price of $6.39 per share and expiration dates on May 2, 2032 and May 26, 2031, respectively. One grant is fully vested, while 22,500 options from the other grant are vested and the remainder vest on May 2, 2026, subject to continued service. Additional Ordinary Shares are held indirectly: shares beneficially owned by his spouse and shares held by an irrevocable trust for his children, for which he disclaims beneficial ownership.